FATE THERAPEUTICS INC

FATE Therapeutics Inc.

Biotechnology • Healthcare • San Diego, CA, United States • FATE (NGM)

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

858 875 1800 12278 Scripps Summit Drive, San Diego, CA 92131, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Biopharmaceutical company Fate Therapeutics works on investigational treatment for lupus - cbs8.com
cbs8.com • Dec 15
Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving Average - Here's Why - MarketBeat
MarketBeat • Jan 1
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
Yahoo Finance • Nov 13
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewswire
GlobeNewswire • Nov 13
Fate Therapeutics Reports Positive Clinical Updates for FT819 in Systemic Lupus Erythematosus and Introduces Next-Generation CAR T-Cell Programs at ASH Annual Meeting | FATE Stock News - Quiver Quantitative
Quiver Quantitative • Dec 8

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has FATE THERAPEUTICS INC had layoffs?
No layoff events have been recorded for FATE THERAPEUTICS INC in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does FATE THERAPEUTICS INC have?
FATE THERAPEUTICS INC has approximately 181 employees.
What industry is FATE THERAPEUTICS INC in?
FATE THERAPEUTICS INC operates in the Biotechnology industry, within the Healthcare sector.
Is FATE THERAPEUTICS INC a publicly traded company?
Yes, FATE THERAPEUTICS INC is publicly traded under the ticker symbol FATE on the NGM. The company has a market capitalization of approximately $0.12 billion.
Where is FATE THERAPEUTICS INC headquartered?
FATE THERAPEUTICS INC is headquartered in San Diego, CA, United States at 12278 Scripps Summit Drive, San Diego, CA 92131, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.